---
title: "Cara Therap (CARA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CARA.US.md"
symbol: "CARA.US"
name: "Cara Therap"
industry: "Pharmaceuticals"
datetime: "2026-04-16T03:40:24.344Z"
locales:
  - [en](https://longbridge.com/en/quote/CARA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CARA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CARA.US.md)
---

# Cara Therap (CARA.US)

## Company Overview

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:15.000Z

**Overall: E (0.90)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 187 / 187 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -65.96% |  |
| Net Profit YoY | 40.20% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 7137000.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -270.01% | E |
| Profit Margin | -992.95% | E |
| Gross Margin | -409.85% | E |
| Revenue YoY | -65.96% | E |
| Net Profit YoY | 40.20% | B |
| Total Assets YoY | -65.17% | E |
| Net Assets YoY | -108.05% | E |
| Cash Flow Margin | -10.07% | D |
| OCF YoY | -65.96% | E |
| Turnover | 0.08 | E |
| Gearing Ratio | 110.48% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cara Therap",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-65.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "40.20%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7137000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-270.01%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-992.95%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-409.85%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-65.96%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "40.20%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-65.17%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-108.05%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-10.07%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-65.96%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.08",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "110.48%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CARA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CARA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CARA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CARA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**